Vitamin B12 and Homocysteine Levels Predict Different Outcomes in Early Parkinson's Disease

on behalf of the Parkinson Study Group—DATATOP Investigators

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: In moderately advanced Parkinson's disease (PD), low serum vitamin B12 levels are common and are associated with neuropathy and cognitive impairment. However, little is known about B12 in early PD. Objective: To determine the prevalence of low vitamin B12 status in early PD and whether it is associated with clinical progression. Methods: We measured vitamin B12 and other B12 status determinants (methylmalonic acid, homocysteine, and holotranscobalamin) in 680 baseline and 456 follow-up serum samples collected from DATATOP participants with early, untreated PD. Borderline low B12 status was defined as serum B12 <184 pmol/L (250 pg/mL), and elevated homocysteine was defined as >15 µmol/L. Outcomes included the UPDRS, ambulatory capacity score (sum of UPDRS items 13-15, 29&30), and MMSE, calculated as annualized rates of change. Results: At baseline, 13% had borderline low B12 levels, 7% had elevated homocysteine, whereas 2% had both. Elevated homocysteine at baseline was associated with worse scores on the baseline MMSE. Analysis of study outcomes showed that compared with the other tertiles, participants in the low B12 tertile (<234 pmol/L; 317 pg/mL) developed greater morbidity as assessed by greater annualized worsening of the ambulatory capacity score. Elevated homocysteine was associated with greater annualized decline in MMSE (−1.96 vs. 0.06; P = 0001). Blood count indices were not associated with B12 or homocysteine status. Conclusions: In this study of early PD, low B12 status was common. Low B12 at baseline predicted greater worsening of mobility whereas elevated homocysteine predicted greater cognitive decline. Given that low B12 and elevated homocysteine can improve with vitamin supplementation, future studies should test whether prevention or early correction of these nutritionally modifiable conditions slows development of disability.

Original languageEnglish (US)
Pages (from-to)762-770
Number of pages9
JournalMovement Disorders
Volume33
Issue number5
DOIs
StatePublished - May 1 2018

Fingerprint

Homocysteine
Vitamin B 12
Parkinson Disease
Serum
Methylmalonic Acid
Vitamins
Outcome Assessment (Health Care)
Morbidity

Keywords

  • cognitive impairment
  • cyanocobalamin
  • gait instability
  • hyperhomocysteinemia

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Vitamin B12 and Homocysteine Levels Predict Different Outcomes in Early Parkinson's Disease. / on behalf of the Parkinson Study Group—DATATOP Investigators.

In: Movement Disorders, Vol. 33, No. 5, 01.05.2018, p. 762-770.

Research output: Contribution to journalArticle

on behalf of the Parkinson Study Group—DATATOP Investigators 2018, 'Vitamin B12 and Homocysteine Levels Predict Different Outcomes in Early Parkinson's Disease', Movement Disorders, vol. 33, no. 5, pp. 762-770. https://doi.org/10.1002/mds.27301
on behalf of the Parkinson Study Group—DATATOP Investigators. / Vitamin B12 and Homocysteine Levels Predict Different Outcomes in Early Parkinson's Disease. In: Movement Disorders. 2018 ; Vol. 33, No. 5. pp. 762-770.
@article{06cd0673078d443ea4432ff2a27b6f9f,
title = "Vitamin B12 and Homocysteine Levels Predict Different Outcomes in Early Parkinson's Disease",
abstract = "Background: In moderately advanced Parkinson's disease (PD), low serum vitamin B12 levels are common and are associated with neuropathy and cognitive impairment. However, little is known about B12 in early PD. Objective: To determine the prevalence of low vitamin B12 status in early PD and whether it is associated with clinical progression. Methods: We measured vitamin B12 and other B12 status determinants (methylmalonic acid, homocysteine, and holotranscobalamin) in 680 baseline and 456 follow-up serum samples collected from DATATOP participants with early, untreated PD. Borderline low B12 status was defined as serum B12 <184 pmol/L (250 pg/mL), and elevated homocysteine was defined as >15 µmol/L. Outcomes included the UPDRS, ambulatory capacity score (sum of UPDRS items 13-15, 29&30), and MMSE, calculated as annualized rates of change. Results: At baseline, 13{\%} had borderline low B12 levels, 7{\%} had elevated homocysteine, whereas 2{\%} had both. Elevated homocysteine at baseline was associated with worse scores on the baseline MMSE. Analysis of study outcomes showed that compared with the other tertiles, participants in the low B12 tertile (<234 pmol/L; 317 pg/mL) developed greater morbidity as assessed by greater annualized worsening of the ambulatory capacity score. Elevated homocysteine was associated with greater annualized decline in MMSE (−1.96 vs. 0.06; P = 0001). Blood count indices were not associated with B12 or homocysteine status. Conclusions: In this study of early PD, low B12 status was common. Low B12 at baseline predicted greater worsening of mobility whereas elevated homocysteine predicted greater cognitive decline. Given that low B12 and elevated homocysteine can improve with vitamin supplementation, future studies should test whether prevention or early correction of these nutritionally modifiable conditions slows development of disability.",
keywords = "cognitive impairment, cyanocobalamin, gait instability, hyperhomocysteinemia",
author = "{on behalf of the Parkinson Study Group—DATATOP Investigators} and Christine, {Chadwick W.} and Peggy Auinger and Amelia Joslin and Yuora Yelpaala and Ralph Green",
year = "2018",
month = "5",
day = "1",
doi = "10.1002/mds.27301",
language = "English (US)",
volume = "33",
pages = "762--770",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",
number = "5",

}

TY - JOUR

T1 - Vitamin B12 and Homocysteine Levels Predict Different Outcomes in Early Parkinson's Disease

AU - on behalf of the Parkinson Study Group—DATATOP Investigators

AU - Christine, Chadwick W.

AU - Auinger, Peggy

AU - Joslin, Amelia

AU - Yelpaala, Yuora

AU - Green, Ralph

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Background: In moderately advanced Parkinson's disease (PD), low serum vitamin B12 levels are common and are associated with neuropathy and cognitive impairment. However, little is known about B12 in early PD. Objective: To determine the prevalence of low vitamin B12 status in early PD and whether it is associated with clinical progression. Methods: We measured vitamin B12 and other B12 status determinants (methylmalonic acid, homocysteine, and holotranscobalamin) in 680 baseline and 456 follow-up serum samples collected from DATATOP participants with early, untreated PD. Borderline low B12 status was defined as serum B12 <184 pmol/L (250 pg/mL), and elevated homocysteine was defined as >15 µmol/L. Outcomes included the UPDRS, ambulatory capacity score (sum of UPDRS items 13-15, 29&30), and MMSE, calculated as annualized rates of change. Results: At baseline, 13% had borderline low B12 levels, 7% had elevated homocysteine, whereas 2% had both. Elevated homocysteine at baseline was associated with worse scores on the baseline MMSE. Analysis of study outcomes showed that compared with the other tertiles, participants in the low B12 tertile (<234 pmol/L; 317 pg/mL) developed greater morbidity as assessed by greater annualized worsening of the ambulatory capacity score. Elevated homocysteine was associated with greater annualized decline in MMSE (−1.96 vs. 0.06; P = 0001). Blood count indices were not associated with B12 or homocysteine status. Conclusions: In this study of early PD, low B12 status was common. Low B12 at baseline predicted greater worsening of mobility whereas elevated homocysteine predicted greater cognitive decline. Given that low B12 and elevated homocysteine can improve with vitamin supplementation, future studies should test whether prevention or early correction of these nutritionally modifiable conditions slows development of disability.

AB - Background: In moderately advanced Parkinson's disease (PD), low serum vitamin B12 levels are common and are associated with neuropathy and cognitive impairment. However, little is known about B12 in early PD. Objective: To determine the prevalence of low vitamin B12 status in early PD and whether it is associated with clinical progression. Methods: We measured vitamin B12 and other B12 status determinants (methylmalonic acid, homocysteine, and holotranscobalamin) in 680 baseline and 456 follow-up serum samples collected from DATATOP participants with early, untreated PD. Borderline low B12 status was defined as serum B12 <184 pmol/L (250 pg/mL), and elevated homocysteine was defined as >15 µmol/L. Outcomes included the UPDRS, ambulatory capacity score (sum of UPDRS items 13-15, 29&30), and MMSE, calculated as annualized rates of change. Results: At baseline, 13% had borderline low B12 levels, 7% had elevated homocysteine, whereas 2% had both. Elevated homocysteine at baseline was associated with worse scores on the baseline MMSE. Analysis of study outcomes showed that compared with the other tertiles, participants in the low B12 tertile (<234 pmol/L; 317 pg/mL) developed greater morbidity as assessed by greater annualized worsening of the ambulatory capacity score. Elevated homocysteine was associated with greater annualized decline in MMSE (−1.96 vs. 0.06; P = 0001). Blood count indices were not associated with B12 or homocysteine status. Conclusions: In this study of early PD, low B12 status was common. Low B12 at baseline predicted greater worsening of mobility whereas elevated homocysteine predicted greater cognitive decline. Given that low B12 and elevated homocysteine can improve with vitamin supplementation, future studies should test whether prevention or early correction of these nutritionally modifiable conditions slows development of disability.

KW - cognitive impairment

KW - cyanocobalamin

KW - gait instability

KW - hyperhomocysteinemia

UR - http://www.scopus.com/inward/record.url?scp=85047837685&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047837685&partnerID=8YFLogxK

U2 - 10.1002/mds.27301

DO - 10.1002/mds.27301

M3 - Article

C2 - 29508904

AN - SCOPUS:85047837685

VL - 33

SP - 762

EP - 770

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - 5

ER -